Nested Therapeutics aims to advance precision oncology medicine by finding new driver mutations hiding in plain sight to reach a broader group of patients.

Precision medicine approaches are making steady progress in reaching more patients, but the fundamental problem of identifying driver alterations hiding in plain sight and uncovering novel targeting mechanisms to tap into a vast array of targets remains a significant bottleneck. Our purpose-built, insightful drug discovery platform enables us to find new, overlooked areas of opportunity in the form of high potential targets and design therapeutics for a perfect fit.

Our science-driven approach and collective drug discovery expertise guides our overarching drug design strategy. We innovate by leveraging mastery in genomics, computational biophysics, machine learning and chemical biology to look closer at molecular mechanisms selected in tumor evolution to ensure nothing is missed – whether mutations that create novel binding pockets are located at the interface of a broader protein complex, or if they are driving changes in protein conformation – we aim to find them.

Our approach has allowed us to advance two programs leveraging novel binding pockets we’ve identified.

Nested’s lead program is NST-628, a non-degrading and fully brain penetrant pan-RAF/MEK molecular glue, that targets multiple critical components in the RAS/MAPK pathway. This differentiated therapeutic mechanism builds on Nested’s proprietary structural insights and has demonstrated superiority relative to single agent and vertical combinations in RAS/MAPK-driven models. NST-628 is currently being evaluated in a global two-part Phase 1 study in patients with MAPK-driven solid tumors.

Nested is leveraging past success in targeting mutation-defined pockets to develop a mutation-selective program in the p53 pathway, an allosteric molecule targeting a transcriptional regulator frequently mutated in cancer. A lead compound with selective target binding to a novel cryptic pocket has been identified.

Our team includes pioneers of precision medicine who are now taking precision oncology to new heights, including highest caliber of academic thought-leaders as founders and advisors as well as a multidisciplinary board with expertise in clinical oncology development, business development, commercial and company building.